A Single-center, Single Group, Dose Escalation, Phase 1 Clinical Trial to Investigate the Safety of TPX-121 in Subjects with Moderate-to-Extreme Nasolabial Folds
Latest Information Update: 26 Dec 2024
At a glance
- Drugs TPX-115 (Primary)
- Indications Nasolabial fold
- Focus Adverse reactions
- Sponsors Tego Science
- 26 Nov 2024 Status changed from not yet recruiting to recruiting.
- 06 Aug 2024 New trial record